Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Y0000090

Finasteride

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

N-(2-methyl-2-propyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide, N-tert-Butyl-3-oxo-4-aza-5α-androst-1-en-17β-carboxamide, MK-906

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C23H36N2O2
CAS Number:
98319-26-7
Molecular Weight:
372.54
MDL number:
MFCD00869737
UNSPSC Code:
41116107
PubChem Substance ID:
329830837
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

finasteride

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

[H][C@@]12CC[C@@]3([H])[C@]4([H])CC[C@H](C(=O)NC(C)(C)C)[C@@]4(C)CC[C@]3([H])[C@@]1(C)C=CC(=O)N2

InChI

1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1

InChI key

DBEPLOCGEIEOCV-WSBQPABSSA-N

Gene Information

human ... SRD5A2(6716)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Finasteride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Selective 5α-reductase inhibitor; antiandrogen.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Health hazardExclamation mark
GHS08,GHS07

Signal Word

Danger

Hazard Statements

H302,H360FD

Hazard Classifications

Acute Tox. 4 Oral - Repr. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 2

1 of 2

Minoxidil United States Pharmacopeia (USP) Reference Standard

USP

1444208

Minoxidil

Ethinyl Estradiol Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1480

Ethinyl Estradiol

Deborah A Finn et al.
CNS drug reviews, 12(1), 53-76 (2006-07-13)
Finasteride is the first 5alpha-reductase inhibitor that received clinical approval for the treatment of human benign prostatic hyperplasia (BPH) and androgenetic alopecia (male pattern hair loss). These clinical applications are based on the ability of finasteride to inhibit the Type
D Berthold et al.
Andrologia, 44 Suppl 1, 836-837 (2011-09-29)
Leydig cell tumours (LCTs) of the testis are rare. Their origin is still unknown. This case report describes a potential relationship between LCT and prolonged exposure to Finasteride.
Souhil Lebdai et al.
BJU international, 105(4), 456-459 (2009-11-26)
Prostate cancer is the most common neoplasm in men. Encouraging results are emerging in prostate cancer risk reduction with 5alpha-reductase (5AR) inhibitors. The Prostate Cancer Prevention Trial (PCPT) showed that prostate cancer risk is reduced by finasteride. However, there was
Anthony V D'Amico et al.
The Journal of urology, 176(5), 2010-2012 (2006-10-31)
We assessed whether the association between the larger changes in prostate specific antigen and high grade prostate cancer observed in the Prostate Cancer Prevention Trial can explain the increased detection of high grade prostate cancer in men randomized to finasteride
Sergio Vañó-Galván et al.
Journal of the American Academy of Dermatology, 70(4), 670-678 (2014-02-11)
To our knowledge, there are no large multicenter studies concerning frontal fibrosing alopecia (FFA) that could give clues about its pathogenesis and best treatment. We sought to describe the epidemiology, comorbidities, clinical presentation, diagnostic findings, and therapeutic choices in a
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service